ISSN 2415-3060 (print), ISSN 2522-4972 (online)
JMBS
  • 2 of 49
Up
JMBS 2019, 4(4): 14–18
https://doi.org/10.26693/jmbs04.04.014
Medicine. Reviews

Features of Functional Indicators in Chronic Obstructive Pulmonary Disease Patients with Obesity

Kuznetsova L. F.1, Gopko О. F.2
Abstract

The review article examines the question of the dependence of some functional parameters in chronic obstructive pulmonary disease patients depending from obesity. The low body mass index was considered an independent risk factor for mortality in chronic obstructive pulmonary disease patients, however, several studies showed a significant aggravation of the respiratory symptoms, limiting physical activity and aggravation the quality of life when chronic obstructive pulmonary disease combine with obesity. Today, the problem of obesity effects on the severity of chronic obstructive pulmonary disease remains unclear, which may be due to differences in research methodology, cohort groups selection, statistical analysis methodology and requires further research for final responses. According to the last recommendations, five clinical phenotypes of chronic obstructive pulmonary disease were identified. One of them is the phenotype of chronic obstructive pulmonary disease with obesity, which develops due to chronic inflammation of low intensity, due to the presence of hormones, neurotransmitters, adipocytokines, pro- and anti-inflammatory interleukins in the adipose tissue, which contribute to the progression of chronic obstructive pulmonary disease, pulmonary insufficiency due to chronic hypoxia. Obesity has a direct effect on the physiology of respiration due to increased chest resistance, limitation of diaphragmatic excursion, dysfunction of the contractile ability of the respiratory muscles. Thus, increase the body weight in chronic obstructive pulmonary disease patients leads to the decrease of FEV1, FVC, FEV1/FVC, residual and total exhalation rates, which confirmed by a number of studies. In addition to the decrease of spirometric indicators, obesity in chronic obstructive pulmonary disease patients significantly reduces tolerance to physical activity and increase the degree of breathlessness. The difference in the physiological response to various loads, the weakness of skeletal muscles and the presence of concomitant diseases is the reason for reducing tolerance to physical activity in chronic obstructive pulmonary disease patients with obesity. For today the question of mechanisms of obesity influence on the functional state of chronic obstructive pulmonary disease patients remains discursive. Possibly, the relationship between diseases is affected by several factors, such as the chronic obstructive pulmonary disease phenotype and the distribution of adipose tissue.

Keywords: chronic obstructive pulmonary disease, obesity, functional indicators

Full text: PDF (Ukr) 205K

References
  1. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22(130): 454–75. https://www.ncbi.nlm.nih.gov/pubmed/24293462. https://doi.org/10.1183/09059180.00008612
  2. Cecere LM, Littman AJ, Slatore CG, Udris EM, Bryson CL, Boyko EJ, et al. Obeity and COPD: Associated Symptoms, Health-related Quality of Life, and Medication Use. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2011; 8(4): 275–84. https://www.ncbi.nlm.nih.gov/pubmed/21809909. https://www.ncbi.nlm.nih.gov/pmc/articles/3169653. https://doi.org/10.3109/15412555.2011.586660
  3. KhOZL v Ukraine: problemy i puti resheniia. Zdorove Ukrainy. 2015; 9/1. Available from: http://health-ua.com/article/15486-hozl-v-ukraine-problemy-i-puti-resheniya [Ukrainian]
  4. Ciavaglia CE, Guenette JA, Ora J, Webb KA, Neder JA, O'Donnell DE. Does exercise test modality influence dyspnoea perception in obese patients with COPD? Eur Respir J. 2014; 43(6): 1621–30. https://www.ncbi.nlm.nih.gov/pubmed/24311769. https://doi.org/10.1183/09031936.00151513
  5. Divo MJ, Cabrera C, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, et al. Comorbidity distribution, clinical expression and survival in COPD patients with different body mass index. Chronic Obstr Pulm Dis. 2014; 1(2): 229–38. https://www.ncbi.nlm.nih.gov/pubmed/28848824. https://www.ncbi.nlm.nih.gov/pmc/articles/5556867. https://doi.org/10.15326/jcopdf.1.2.2014.0117
  6. Fabbri L, Luppi F, Beghe B, Rabe K. Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31(1): 204-12. https://www.ncbi.nlm.nih.gov/pubmed/18166598. https://doi.org/10.1183/09031936.00114307
  7. Feshchenko Y, Iashyna L, Nugmanova D, Gyrina O, Polianska M, Markov A, et al. Chronic obstructive pulmonary disease, bronchial asthma and allergic rhinitis in the adult population within the commonwealth of independent states: rationale and design of the CORE study. BMC Pulm Med. 2017 Oct 10; 17(1): 131. https://www.ncbi.nlm.nih.gov/pubmed/29017524. https://www.ncbi.nlm.nih.gov/pmc/articles/5634889. https://doi.org/10.1186/s12890-017-0471-x
  8. Gagnon P, Guenette J, Langer D, Laviolette L, Mainguy V, Maltais F, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9(1): 187–201. https://www.ncbi.nlm.nih.gov/pubmed/24600216. https://www.ncbi.nlm.nih.gov/pmc/articles/3933347. https://doi.org/https://doi.org/10.2147/COPD.S38934
  9. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, revised 2018. (GOLD 2018). Clobal initiative for Cronic Obstructive Lung Disease, Inc., 2018. 142 p.
  10. Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. Chest. 2006; 130(3): 827–33. https://www.ncbi.nlm.nih.gov/pubmed/16963682. https://doi.org/10.1378/chest.130.3.827
  11. Katz Р, Iribarren C, Sanchez G, Blanc PD. Obesity and Functioning Among Individuals with Chronic Obstructive Pulmonary Disease (COPD). COPD: Journal of Chronic Obstructive Pulmonary Disease. 2016; 13(3): 352-9. https://www.ncbi.nlm.nih.gov/pubmed/26683222. https://www.ncbi.nlm.nih.gov/pmc/articles/4951092. https://doi.org/10.3109/15412555.2015.1087991
  12. Korean Endocrine Society and Korean Society for the Study of Obesity. Management of obesity, 2010 recommendation. Endocrinol Metab. 2010; 25(4): 301–4. doi: 10.3803/EnM.2010.25.4.301
  13. Maatman RC, Spruit MA, van Melick PP, Peeters JP, Rutten EP, Vanfleteren LE, et al. Effects of obesity on weight-bearing versus weight-supported exercise testing in patients with COPD. Respirology. 2016; 21(3): 483-8. https://www.ncbi.nlm.nih.gov/pubmed/26647921. https://doi.org/10.1111/resp.12700
  14. Makarevich AE. K probleme klinicheskikh fenotipov khronicheskoi obstruktivnoi bolezni legkikh. Praktikuiuchii lіkar. 2016; 3: 57–67. [Ukrainian]
  15. Nugmanova D, Feshchenko Y, Iashyna L, Gyrina O, Malynovska K, Mammadbayov E, et al. BMC Pulmonary Medicine The prevalence, burden and risk factors associated with chronic obstructive pulmonary disease in Commonwealth of Independent States (Ukraine, Kazakhstan and Azerbaijan): results of the CORE study (2018). BMC Pulm Med. 2018; 18: 26. https://www.ncbi.nlm.nih.gov/pubmed/29382317. https://www.ncbi.nlm.nih.gov/pmc/articles/5791247. https://doi.org/10.1186/s12890-018-0589-5
  16. O'Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide: physiological and clinical consequences. Ann Am Thorac Soc. 2014; 11(4): 635–44. https://www.ncbi.nlm.nih.gov/pubmed/24625243. https://doi.org/10.1513/AnnalsATS.201312-438FR
  17. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O’Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. J Appl Physiol. 2011; 111(1): 10–19. https://www.ncbi.nlm.nih.gov/pubmed/21350021. https://doi.org/10.1152/japplphysiol.01131.2010
  18. Park JH, Lee JK, Heo EY, Kim DK, Chung HS. The effect of obesity on patients with mild chronic obstructive pulmonary disease: results from KNHANES 2010 to 2012. Int J Chron Obstruct Pulmon Dis. 2017; 12: 757–63. https://www.ncbi.nlm.nih.gov/pubmed/28280320. https://www.ncbi.nlm.nih.gov/pmc/articles/5338838. https://doi.org/10.2147/COPD.S126192
  19. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5): 948–68. https://www.ncbi.nlm.nih.gov/pubmed/16264058. https://doi.org/10.1183/09031936.05.00035205
  20. Petrovic M, Reiter M, Zipko H, Pohl W, Wanke T. Effects of inspiratory muscle training on dynamic hyperinflation in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7: 797–805. https://www.ncbi.nlm.nih.gov/pubmed/23233798. https://www.ncbi.nlm.nih.gov/pmc/articles/3516469. https://doi.org/10.2147/COPD.S23784
  21. Rodrı´guez DA, Garcia-Aymerich J, Valera JL, Sauleda J, Togores B, Galdiz JB, et al. a on behalf of the PAC-COPD Study Group. Determinants of exercise capacity in obese and non-obese COPD patients. Respiratory Medicine. 2014; 108: 745–51. https://www.ncbi.nlm.nih.gov/pubmed/24565602. https://doi.org/10.1016/j.rmed.2014.02.004
  22. Şahin HD, Naz İ, Varol Y, Kömürcüoğlu B. The effect of obesity on dyspnea, 6 minute walk distance, walk work and workload in patients with COPD. European Respiratory Journal. 2017; 50: PA692. https://doi.org/10.1183/1393003.congress-2017.PA692
  23. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Health Organization, 2000. Available from: http://www.who.int/iris/handle/10665/42330
  24. Ohiienko VP. Statystychni dani po poshyrenniu ozhyrinnia v Ukraini i sviti zahalom. Available from: http://medstat.gov.ua/ukr. [Ukrainian]
  25. Ospanova TS, Bilchenko OS, Bolokadze YeO. Deiaki fenotypy u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen. Eksperymentalna i klinichna medytsyny. 2015; 4(69): 48–52. [Ukrainian]
  26. Ostrovskyi MM, Herych PR. Do pytannia polimorbidnosti ta komorbidnosti u khvorykh na KhOZL. Ukr pulmonolohichnyi zhurn. 2011; 4: 19–24. [Ukrainian]
  27. Radchenko OM, Pylypiv LI. Vplyv ozhyrinnia na funktsiiu zovnishnoho dykhannia u patsiientiv z khronichnym obstruktyvnym zakhvoriuvanniam lehen. Zhurnal klinichnykh ta eksperymentalnykh medychnykh doslidzhen. 2017; 5(1): 593–6. [Ukrainian]
  28. Tolokh OS, Rudnytska ND, Chulovska UB, Volnytska KhI. Optymizatsiia terapii KhOZL z urakhuvanniam klinichnoho fenotypu. Klin imunolohiia. Alerholohiia. Infektolohiia. 2015; 9/10: 3–10. [Ukrainian]